Press Releases June 3, 2026 04:05 PM

Reed’s Receives NYSE Deficiency Notification Regarding Stockholders’ Equity

Reed's Receives NYSE American Deficiency Notice Over Low Stockholders' Equity and Consecutive Net Losses

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
REED

Reed's, Inc., a US-based natural ginger beverage company listed on NYSE American, announced it received a notification from the exchange citing non-compliance with listing standards due to low stockholders' equity ($2.7 million) and net losses in its last five fiscal years. The company must submit a plan by June 28, 2026, to regain compliance by November 29, 2027, while continuing to list on NYSE American during the cure period.

Reed’s Receives NYSE Deficiency Notification Regarding Stockholders’ Equity
REED
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Reed's reported stockholders' equity of $2.7 million at March 31, 2026, below NYSE American standards.
  • The company has experienced net losses in five consecutive fiscal years, triggering listing deficiency notice.
  • Reed's must submit a plan addressing compliance by June 28, 2026, aiming to regain listing adherence by late 2027.
  • Sectors impacted include beverages, consumer discretionary, and capital markets due to listing compliance issues.

NORWALK, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, announced that on May 29, 2026, the Company received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) that the Company is below compliance with Sections 1003(a)(ii) and (iii) of NYSE American’s listing standards set forth in Part 10 of the NYSE American Company Guide (the “Company Guide”) because the Company reported stockholders’ equity of $2.7 million at March 31, 2026 and had net losses in its five most recent fiscal years. The Company is also not currently eligible for any exemption in Section 1003(a) of the Company Guide from the stockholders’ equity requirements.

In connection with its non-compliance with Sections 1003(a)(ii) and (iii) of the Company Guide, the Company must submit a plan by June 28, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by November 29, 2027. During the eighteen-month cure period, the Company’s common stock will continue to be listed and traded on NYSE American, subject to the Company’s continued compliance with the NYSE American’s other applicable listing rules.

About Reed’s, Inc.

Reed’s is an innovative company and category leader that provides the world with high quality, premium and better-for-you sodas. Established in 1989, Reed's is a leader in craft beverages under the Reed’s®, Virgil’s® and Flying Cauldron® brand names. The Company’s beverages are now sold in over 32,000 stores nationwide.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements. These forward-looking statements may be identified by terms such as ““believe,”“ “expect,” “intends,” “outlook,” “may,” “will” and similar expressions. Forward-looking statements include, but are not limited to, statements herein with respect to implied or express statements regarding the Company’s expectations surrounding the submission of a plan and regaining compliance with the NYSE American’s continued listing standards, and actions of the Company and/or the NYSE American to be taken with respect to matters discussed in the Notice. These forward-looking statements are based on current expectations. The achievement or success of the matters covered by such forward-looking statements involves risks, uncertainties, and assumptions, many of which involve factors or circumstances that are beyond our control. These risks could cause actual results to differ materially from those discussed in such forward-looking statements.

The risks and uncertainties referred to above include, but are not limited to: Reed’s ability to timely submit its plan to NYSE American, the acceptance of its plan by NYSE American and Reed’s ability to regain compliance with the listing standards set forth in the Company Guide by November 29, 2027, and other risks detailed from time to time in Reed’s public filings, including Reed’s annual report on Form 10-K filed on March 25, 2026, which will be available on the Securities and Exchange Commission’s web site at www.sec.gov. These forward-looking statements are based on current expectations and speak only as of the date hereof. Reed’s assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Investor Relations Contact

Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
[email protected]
(720) 330-2829


Risks

  • Risk of delisting if Reed's fails to regain compliance with NYSE American standards within the cure period, impacting shareholder value and liquidity.
  • Uncertainty over acceptance of the company's compliance plan by NYSE American.
  • Continued financial losses that may hamper company's ability to strengthen equity and meet listing requirements, affecting investor confidence.

More from Press Releases

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026 Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems Jun 5, 2026 Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study Jun 5, 2026